Royalty Research And Ddevelopement To Revenue from 2010 to 2025

RPRX Stock  USD 33.38  0.31  0.92%   
Royalty Pharma Research And Ddevelopement To Revenue yearly trend continues to be fairly stable with very little volatility. Research And Ddevelopement To Revenue will likely drop to 0.0008 in 2025. Research And Ddevelopement To Revenue is the ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services. View All Fundamentals
 
Research And Ddevelopement To Revenue  
First Reported
2010-12-31
Previous Quarter
0.00088339
Current Value
0.000839
Quarterly Volatility
0.05002782
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 237.3 M, Total Revenue of 2.4 B or Research Development of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.79, Dividend Yield of 0.0362 or PTB Ratio of 1.05. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Research And Ddevelopement To Revenue Growth Pattern

Below is the plot of the Research And Ddevelopement To Revenue of Royalty Pharma Plc over the last few years. It is the ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services. Royalty Pharma's Research And Ddevelopement To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Research And Ddevelopement To Revenue10 Years Trend
Pretty Stable
   Research And Ddevelopement To Revenue   
       Timeline  

Royalty Research And Ddevelopement To Revenue Regression Statistics

Arithmetic Mean0.06
Geometric Mean0.03
Coefficient Of Variation84.56
Mean Deviation0.03
Median0.06
Standard Deviation0.05
Sample Variance0
Range0.2179
R-Value(0.25)
Mean Square Error0
R-Squared0.06
Significance0.35
Slope(0)
Total Sum of Squares0.04

Royalty Research And Ddevelopement To Revenue History

2025 8.39E-4
2024 8.83E-4
2023 0.0221
2022 0.0792
2021 0.0874
2020 0.0123
2019 0.0458

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Research And Ddevelopement To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.